Reuters logo
BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine
2017年4月28日 / 晚上6点31分 / 6 个月前

BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine

April 28 (Reuters) - Alder Biopharmaceuticals Inc

* Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion

* Single administration of Eptinezumab showed safety profile similar to placebo; no serious adverse events deemed treatment related

* Alder Biopharmaceuticals Inc announces presentation of positive data from phase 2b clinical trial evaluating eptinezumab for prevention of migraine Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below